Figure 1 from Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Authors: Saner Flurina A.M. , Takahashi Kazuaki , Budden Timothy , Pandey Ahwan , Ariyaratne Dinuka , Zwimpfer Tibor A. , Meagher Nicola S. , Fereday Sian , Twomey Laura , Pishas Kathleen I. , Hoang Therese , Bolithon Adelyn , Traficante Nadia , Alsop Kathryn , Christie Elizabeth L. , Kang Eun-Young , Nelson Gregg S. , Ghatage Prafull , Lee Cheng-Han , Riggan Marjorie J. , Alsop Jennifer , Beckmann Matthias W. , Boros Jessica , Brand Alison H. , Brooks-Wilson Angela , Carney Michael E. , Coulson Penny , Courtney-Brooks Madeleine , Cushing-Haugen Kara L. , Cybulski Cezary , El-Bahrawy Mona A. , Elishaev Esther , Erber Ramona , Gayther Simon A. , Gentry-Maharaj Aleksandra , Gilks C. Blake , Harnett Paul R. , Harris Holly R. , Hartmann Arndt , Hein Alexander , Hendley Joy , Hernandez Brenda Y. , Jakubowska Anna , Jimenez-Linan Mercedes , Jones Michael E. , Kaufmann Scott H. , Kennedy Catherine J. , Kluz Tomasz , Koziak Jennifer M. , Kristjansdottir Björg , Le Nhu D. , Lener Marcin , Lester Jenny , Lubiński Jan , Mateoiu Constantina , Orsulic Sandra , Ruebner Matthias , Schoemaker Minouk J. , Shah Mitul , Sharma Raghwa , Sherman Mark E. , Shvetsov Yurii B. , Soong T. Rinda , Steed Helen , Sukumvanich Paniti , Talhouk Aline , Taylor Sarah E. , Vierkant Robert A. , Wang Chen , Widschwendter Martin , Wilkens Lynne R. , Winham Stacey J. , Anglesio Michael S. , Berchuck Andrew , Brenton James D. , Campbell Ian , Cook Linda S. , Doherty Jennifer A. , Fasching Peter A. , Fortner Renée T. , Goodman Marc T. , Gronwald Jacek , Huntsman David G. , Karlan Beth Y. , Kelemen Linda E. , Menon Usha , Modugno Francesmary , Pharoah Paul D.P. , Schildkraut Joellen M. , Sundfeldt Karin , Swerdlow Anthony J. , Goode Ellen L. , DeFazio Anna , Köbel Martin , Ramus Susan J. , Bowtell David D.L. , Garsed Dale W. 
Published: August 2024

<p>Expression of RB1 and survival associations across ovarian cancer histotypes. <b>A,</b> Representative images of IHC detection of RB1 expression in ovarian carcinoma tissues, showing examples of the three most common expression patterns: retained, lost, and subclonal loss. <b>B,</b> Proportion of patients with loss or retention of RB1 protein expression in tumor samples by ovarian cancer histotypes. <i>χ</i><sup>2</sup><i>P</i> value reported for difference in proportions across all histotypes. CCOC, clear cell ovarian cancer; LGSC, low-grade serous carcinoma; MOC, mucinous ovarian cancer. <b>C,</b> Boxplots show <i>RB1</i> mRNA expression (NanoString) by RB1 protein expression status; lines indicate median and whiskers show range (Mann–Whitney test <i>P</i> value reported). Kaplan–Meier analysis of OS in patients diagnosed with HGSC (<b>D</b>) and ENOC (<b>E</b>) stratified by tumor RB1 expression. <b>F,</b> Frequency of germline <i>BRCA</i> wild-type (g<i>BRCA</i>wt) and germline <i>BRCA</i> pathogenic variants (g<i>BRCA</i>var) in patients with HGSC stratified by RB1 protein expression. χ<sup>2</sup><i>P</i> value is reported. <b>G,</b> Kaplan–Meier estimates of overall survival in patients with HGSC by combined germline <i>BRCA</i> and tumor RB1 expression status.</p>